Abstract
One of the most promising areas in medicine is the so called personalized medicine where pharmacogenetic approach has a clear role [4]. However, the developments in the pharmacogenetic field of psychiatric disorders have not been as quick as in other areas of medicine. This scenario is even slower for child and adolescents mental disorders. In this issue of the journal, Blazquez et al. [1] present an extensive review of the literature describing how certain genes are involved in the pharmacodynamics and pharmacokinetics of fluoxetine in children and adolescents. Initial exciting findings seem to suggest a potential role for polymorphisms in several genes like SLC6A4, HTR1A and MAO-A as moderators of response to fluoxetine in depression. Nevertheless, the authors clearly document the scarcity of studies and the diversity of methodology in the investigations hampering any chance of a major step in defining a more personalized treatment for this disorder at the present moment. Other relevant research areas in child mental health with impact on clinical work are: (1) the role of environmental factors in child mental disorders, specially smoking during pregnancy in ADHD; and (2) the need of developing friendly non-pharmacological interventions that can help individuals with mental disorders dealing with the impact of symptoms in their daily lives. There is an unresolved debate in the literature on the real role of smoking during pregnancy in the etiology of ADHD with several authors suggesting that the association found might be solely a product of not controlled confounding variables like the genetic predisposition for ADHD (see Motlagh et al. [6] and Thapar et al. [7]). In this issue of the journal, Ellis et al. [5] add interesting findings for this discussion. In a community sample of 995 4-year olds from Norway, they found increased odds for both ADHD and ODD in offspring of mothers that smoked during pregnancy, even after adjusting for potential confounding variables by using the propensity score. Obviously, if a real association exists between smoking during pregnancy and externalizing disorders in children, the implications for public mental health are enormous. Developmental psychopathology has emphasized the intimate relation between child and adult mental disorders. Pharmacological interventions are key tools for treating core symptoms of some mental disorders like ADHD [2]. However, clinicians are left without many evidence-based options for helping their patients to deal with increasing environmental demands, even more when they grow up entering adulthood. Thus, there is a clear need to test potential interventions in the real world addressing this shortcoming. In this context, Wentz et al. [9] applied a user-centered design to develop a model for internet-based support and coaching for adolescents and adults with ADHD and ASD. The intervention is a mix of support sessions via internet (chat) and two additional in-person meetings. It was designed to last 8 weeks and the model was validated in a pilot study with ten individuals with ASD and/or ADHD. Since quality of life seems to be seriously impaired by ADHD (see Danckaerts et al. [3]), one reassuring finding was an improvement in subjective quality of life at follow-up. Although replication is needed before any firm conclusion on the efficacy of the intervention might be defined, the field certainly welcomes this kind of initiatives. Finally, but yet in the context of developmental psychopathology, roads from certain temperamental aspects L. A. Rohde (&) Department of Psychiatry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil e-mail: lrohde@terra.com.br
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have